Fig. 2From: Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case reporta) FRα staining b) Changes in CA125 levels during treatment with mirvetuximab soravtansine monoclonal antibodyBack to article page